Cancer Immunology, Immunotherapy《癌症免疫学与免疫治疗》(可网站投稿)

Cancer Immunology, Immunotherapy《癌症免疫学与免疫治疗》(月刊). Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

杂志简称:cancer immunol immun
中文译名:《癌症免疫学与免疫治疗》
收录属性:scie(2024版), 目次收录(维普), 目次收录(知网),英文期刊,
自引率:3.20%
投稿方向:医学、immunology免疫学、oncology肿瘤学

Cancer Immunology, Immunotherapy《癌症免疫学与免疫治疗》

SCI/E期刊基本信息

出版周期:月刊 地区:美国
中科院分区:2区
是否TOP:非TOP期刊
是否综述:非综述期刊
是否OA:非OA期刊
国际标准刊号:ISSN 0340-7004;EISSN 1432-0851
杂志语言:英语
出版国家:美国

杂志官网 联系方式

出版地址:ONE NEW YORK PLAZA,SUITE 4600 ,NEW YORK,United States,NY,10004
杂志邮箱:
投稿网址:https://www.editorialmanager.com/ciim
杂志官方网址:https://www.springer.com/journal/262
出版商网址:http://www.springeronline.com

杂志投稿要求

期刊相关咨询邮箱【杂志社官方网站信息】

Contact the journal

Submission-related enquiries

Queries about submission issues, peer review process, or the status of your manuscript should be sent to Karthiga Anbalagan (Karthiga.Anbalagan@springernature.com).

Production-related enquiries

Queries about accepted manuscripts in production or post-publication corrections should be sent to Anburaj Sundaram (Anburaj.Sundaram@springer.com).

Rights and Permissions enquiries

For permission requests to reuse or reprint content, please follow the link ‘Rights and permissions’ on the relevant article page. For other queries, contact journalpermissions@springernature.com.

Publication-related enquiries

Queries related to journal publishing should be sent to Mehak Massand (mehak.massand@springer.com).

投稿须知【杂志社官方网站信息】

Cancer Immunology, Immunotherapy

Submission guidelines

Instructions for Authors

Types of Papers

The journal Cancer Immunology, Immunotherapy publishes the following types of papers:

o Original research articles – featuring three innovations: new concept, new mechanism or new therapy, in basic science and clinical studies, text limit 4000 words, 45 references, 8 figures/3 tables limit.

o Brief research reports – featuring clear and concise conclusion supported by solid data at small-scale basic research or early stage of clinical studies, 2000 words, 20 references, 4 figure limit / 2 table limit.

o Review – featuring commentary, opinion, meeting summary. The objective is to provide a balanced, comprehensive review of current knowledge and advances on certain topics or technology, limit 4000 words, 40 references and 2 explanatory items (figure / table).

o Letter to the Editors – This journal occasionally accepts letters to the Editors pertaining primarily to articles published in the Journal. Text is limited to 750 words, with no abstract and no keywords. There may be one figure, up to five references, and no more than three authors, with author affiliations only including main institution, place name and (state plus) country (i.e. no departments, etc.).

o Meta-analysis Reviews – Must be based on a rigorous methodological/statistical approach described in detail in the methods section applied to a relevant clinical or basic research issue. Word limit is 3000 with no more than 100 references. Meta-Analyses and systematic reviews must adhere to the recommendations of the PRISMA document (http://prisma-statment.org).

o Clinical Trial Reports – please review the

guidelines of Original research Articles and include relevant immunological data.

o Editorials- it is a forum for exchanging ideas, innovations, new updates in a fast-moving field or topic. Word limitation 1200 with up to 10 references and one figure or table.

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit manuscript” on the right and upload all of your manuscript files following the instructions given on the screen.

Please ensure you provide all relevant editable source files. Failing to submit these source files might cause unnecessary delays in the review and production process.

刊知网 精心整理,转载请注明出处:https://www.kanzhiwang.com/archives/44335

我要点评 请您把投稿经验分享出来 让大家少走弯路少踩坑,我为人人、人人为我。

内容纠错 杂志信息如有错漏 请在下方留言。

上一篇 2025年2月26日 下午10:25
下一篇 2025年2月26日 下午10:31

相关推荐

发表回复

登录后才能评论

联系我们

191 1833 1195

QQ:321628655
邮件:321628655@qq.com

工作时间:周一至周五,9:30-18:30,节假日休息